AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announced a strategic partnership with Beluga Health, P.A., through a newly signed Collaborative Services Agreement, according to a June 29 release.
This partnership is set to revolutionize the delivery of longitudinal care, population health, and quality improvement by integrating DarioHealth's multi-condition engagement platform with Beluga's extensive physician-led clinical network that spans all 50 states.
This collaboration enables a comprehensive health management system where monitoring, detection, and treatment of various health conditions — including hypertension, diabetes, obesity, behavioral health, and musculoskeletal issues — are unified under a single platform. This integration facilitates a seamless transition from initial detection of a health issue to direct clinical intervention by a prescribing clinician, thereby enhancing the efficiency and effectiveness of patient care.
"Health plans and providers don't need more point solutions — what they need is integrated execution that actually moves the needle on quality, cost, and revenue," DarioHealth Chief Executive Officer Erez Raphael said.
He highlighted how the partnership with Beluga enhances DarioHealth's ability to manage escalating health conditions and convert engagement into tangible, provider-delivered treatments, thereby impacting areas critical to health plans such as Star ratings and total cost of care.
DarioHealth distinguishes itself from other engagement platforms by offering a solution that evolves with each patient's needs, avoiding the common practice of transferring patients between different care providers. The effectiveness of DarioHealth's platform is supported by data; a study published in JMIR showed that DarioHealth users experienced 23% lower hospitalization rates and 26% lower total charges compared to patients receiving usual care.
Paving the Way for the Company to Enter New Markets
The agreement with Beluga positions DarioHealth as a quality and revenue performance partner for health plans that delivers impact based on where plans are economically incentivized, the release noted.
Notably, even a minor improvement in CMS Star Ratings, such as a half-star gain, could translate to approximately $500 per member, while addressing gaps in risk-adjustment documentation could save over $1,000 per member annually.
"Beluga's white-label medical infrastructure addresses this without DarioHealth building or operating a provider network, thereby expanding contract value per client at high margin," the company said.
DarioHealth said the partnership also paves the way for the company to enter new markets. Currently serving 12 health plans, including three national ones, DarioHealth can now leverage this existing network to introduce the joint solution to more members. The integrated system opens doors to new segments such as state Medicaid programs, federal Rural Health Transformation initiatives, and direct health-system partnerships, which increasingly demand tangible proof of clinical action.
Dr. Jonah Mink, co-founder and CEO of Beluga Health, remarked on the synergy between the two companies, noting, "Collaborating with DarioHealth allows us to extend that impact upstream, activating members earlier and sustaining engagement in a way that makes high-quality care delivery more impactful, scalable and economically meaningful."
He praised the consumer-first approach shared by both companies, which he believes is key to the successful integration of their services.
Co. Makes Strategic Advisory Board Appointment
On June 30, the company announced the addition of Sean O'Reilly to its Advisory Board as part of DarioHealth's strategic initiative to enhance its guidance as it progresses with its channel partner-led growth strategy, aiming to broaden its reach across payer, provider, and employer markets.
O'Reilly brings a wealth of experience in healthcare compliance, risk management, regulatory oversight, and legal expertise, spanning various sectors including Medicare Advantage, Medicaid, employer group medical and specialty insurance, military healthcare, hospice, home health, value-based primary care, and pharmacy benefit management, the release noted. His extensive background positions him as a valuable asset in supporting DarioHealth's expansion and operational strategies.
"Sean brings an exceptional combination of healthcare compliance leadership, operational and payer industry expertise, as well as M&A experience," DarioHealth Chief Executive Officer Erez Raphael said.
Raphael emphasized that O'Reilly's insights will be crucial as DarioHealth seeks to enhance its healthcare relationships, accelerate the adoption of its AI-powered platforms for behavioral health and chronic condition management, and advance its care delivery capabilities.
"Dario is operating in one of the most important areas of healthcare, where digital engagement, clinical impact, regulatory confidence and measurable value must come together," O'Reilly said. He highlighted the alignment of DarioHealth's platform with the current needs of health plans, providers, and employers for scalable solutions that not only improve outcomes but also uphold accountability and operational excellence.
Before joining DarioHealth's Advisory Board, O'Reilly had an extensive career at Humana, where he spent over 13 years and held the position of senior vice president and chief compliance officer. In this role, he led comprehensive compliance programs across a range of healthcare services. His expertise in utilizing advanced data analytics and AI to enhance compliance and operational performance is particularly relevant to DarioHealth's focus on delivering measurable health outcomes through innovative technological solutions. Additionally, O'Reilly is a licensed attorney with a strong background in mergers and acquisitions, integrating aspects of privacy, ethics, and technology-driven risk analysis to fortify compliance culture, support operational integrity, and foster strategic growth. His multifaceted experience and legal acumen are expected to significantly contribute to DarioHealth's ongoing expansion and success in the digital health landscape.
Analyst Praises Shift in Business Model
In an analysis dated April 27, Ashok Kumar, PhD, CFA, from ThinkEquity, reaffirmed a "BUY" rating and a price target of US$25 for DarioHealth. Kumar's report presents a cautiously optimistic outlook, emphasizing that "the reported evidence still supports a constructive, but risk-adjusted, view." He highlighted improvements in DarioHealth's financial performance, noting a reduction in operating expenses and an increase in gross margin, which he believes are not fully recognized by the market.
The report detailed DarioHealth's financial results for 2025, revealing a revenue of US$22.4 million, a decrease from US$27 million in 2024. This decline was attributed by management to a scope change and the non-renewal of a contract with a legacy Twill client. Despite this setback, DarioHealth signed 85 new agreements in 2025 and identified US$12.9 million in contracted and late-stage Annual Recurring Revenue (ARR) expected to contribute in 2026 and 2027. The company also reported a substantial pipeline valued at US$122 million at the end of the year.
Kumar pointed out that the financial strength of DarioHealth is most evident when focusing on reported metrics, such as the increase in GAAP gross margin from 49% in 2024 to 57% in 2025. Additional disclosures from the company's March 19 earnings materials and an April 2026 investor presentation indicated that the core B2B2C recurring business maintained an approximately 80% non-GAAP gross margin.
The analyst also discussed the strategic shift in DarioHealth's business model, moving from narrow point-solution selling to a broader approach centered around multi-condition deployments tailored for employers, health plans, and various channels. This shift is supported by the fact that the majority of new contracts in 2025 were for multi-condition platforms, and more than 70% of the pipeline opportunities were also multi-condition.
Kumar's report also touched on DarioHealth's commercial pipeline and channel activities, noting that the pipeline had reached US$122 million across 230 opportunities by the end of 2025, with a significant portion being multi-condition opportunities. He mentioned ongoing ramp-up timings for relationships with key partners such as Florida Blue, Amwell, HCSC, and Solera.
"We think the core factual setup is better than it was a year ago: reported operating expense is lower, gross margin is higher, the evidence package is broader, and the company has disclosed enough signed and late-stage commercial activity to support a reasonable growth bridge if even part of it converts on schedule," Kumar wrote.
Unifying Digital Health Services in One Platform
CG Capital has reaffirmed its "Outperform" rating and a price target of US$28 for DarioHealth in its recent updates, based on the company's performance and strategic developments reported in the first quarter of 2026.
On May 13, 2026, DarioHealth announced its first-quarter results, which showed a continuation of the revenue growth and operational improvements that began in the last quarter of 2025.
DarioHealth has successfully integrated its formerly separate digital health services — spanning diabetes, hypertension, musculoskeletal, and behavioral health — into a unified platform under the DarioIQ AI architecture. This platform now supports over six chronic conditions and is backed by more than 100 peer-reviewed studies, enhancing the member experience across various health metrics.
In 2025, DarioHealth exceeded its targets by signing 85 enterprise agreements, doubling its goal of 40. These agreements are part of a broader commercial expansion that includes significant relationships with major health plans such as Aetna/CVS, UnitedHealthcare, and Florida Blue, CG Capital said. The company's commercial pipeline has grown to US$127 million, encompassing 241 B2B2C opportunities, up from US$122 million and 230 opportunities at the end of 2025.
The firm also noted early positive outcomes from the DarioIQ platform, which has shown up to a 40% improvement in member retention and a 57% increase in active sessions compared to a control group. These metrics underscore the platform's effectiveness in engaging and retaining users, which is critical for long-term success in digital health markets.
The Catalyst: Chronic Diseases Are a Key Driver for Digital Health Adoption
A recent report from MarketsandMarkets, dated May 21, forecasts significant growth in the global digital health market, projecting an increase from US$199.1 billion in 2025 to US$573.5 billion by 2030. This growth represents a compound annual growth rate of 23.6%. The report attributes this expansion to the "rising adoption of telehealth, wearable devices, mobile health applications, and AI-powered healthcare platforms," which are revolutionizing interactions between patients and healthcare providers across the healthcare ecosystem.
Chronic diseases are highlighted as a key driver of digital health adoption. The report points out that "the growing elderly population and rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and neurological conditions" are fueling the demand for digital healthcare solutions. Technologies such as remote monitoring systems, AI-enabled diagnostics, and connected care platforms are increasingly being utilized to provide continuous and personalized care. These technologies also help in reducing the frequency of hospital visits and alleviating operational burdens on healthcare facilities.
Streetwise Ownership Overview*
DarioHealth Corp. (DRIO:NASDAQ)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 11/18/19 | DRIO | 20 | DRIO | 1 |
| 03/20/13 | LSYI | 1 | DRIO | 1 |
Artificial intelligence is playing a crucial role in this sector's growth, becoming increasingly central to the development of intelligent healthcare ecosystems. According to the report, AI-powered analytics, predictive diagnostics, and automated clinical workflows are enhancing decision-making capabilities and improving patient outcomes. The integration of AI with wearable sensors, cloud platforms, and connected devices is facilitating personalized treatment strategies and enabling real-time patient monitoring.
The report also notes that diabetes is the largest disease segment within the digital health market as of 2024. This dominance is driven by the demand for continuous monitoring and long-term management of the disease. Technologies such as connected glucose meters, continuous glucose monitoring systems, and AI-powered diabetes management applications are not only improving patient engagement and treatment personalization but are also seamlessly integrating into routine clinical workflows.
According to a report titled "The Impact of Digital Health Technologies on Chronic Disease Management" by Muhammed Asif and Pramod K. Gaur, "Advances in digital health technologies have the potential to redesign chronic disease management and enable new directions for better patient outcomes and improved healthcare delivery."
The study continued, "Investing in digital health solutions and innovation makes it possible for the healthcare industry to maintain quality of care, achieve better patient outcomes, and lower the burden of chronic diseases on a healthcare system."
Ownership and Share Information1
DarioHealth Corp. has a market cap of US$51.41 million, with 7.3 million shares outstanding.
The company's 52-week range is US$5.84-US$17.74.
Institutions own 39.4% of shares, while Strategic Investors own 7.5%.
Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.
| Want to be the first to know about interesting Healthcare Services and Life Sciences Tools & Diagnostics investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- DarioHealth Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
